2022
1047P Lung-MAP S1800A: Exploratory analysis of prior immunotherapy outcomes on OS with ramucirumab plus pembrolizumab for NSCLC with PD on prior ICI
Reckamp K, Redman M, Dragnev K, Villaruz L, Faller B, Al Baghdadi T, Hines S, Minichiello K, Gandara D, Kelly K, Herbst R. 1047P Lung-MAP S1800A: Exploratory analysis of prior immunotherapy outcomes on OS with ramucirumab plus pembrolizumab for NSCLC with PD on prior ICI. Annals Of Oncology 2022, 33: s1033. DOI: 10.1016/j.annonc.2022.07.1173.Peer-Reviewed Original Research
2019
MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF)
Herbst R, Arkenau H, Bendell J, Arrowsmith E, Wermke M, Soriano A, Penel N, Santana-Davila R, Bischoff H, Chau I, Chao B, Ferry D, Mi G, Paz-Ares L. MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF). Journal Of Thoracic Oncology 2019, 14: s307. DOI: 10.1016/j.jtho.2019.08.615.Peer-Reviewed Original ResearchSO-002 Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)
Chau I, Bendell J, Soriano A, Arkenau H, Cultrera J, Santana-Davila R, Calvo E, Le Tourneau C, Zender L, Mi G, Schelman W, Ferry D, Herbst R, Fuchs C. SO-002 Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF). Annals Of Oncology 2019, 30: iv122. DOI: 10.1093/annonc/mdz157.001.Peer-Reviewed Original Research
2017
O-019 Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study
Arkenau H, Bendell J, Herbst R, Mi G, Jin J, Rege J, Ferry D, Chau I. O-019 Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study. Annals Of Oncology 2017, 28: iii144-iii145. DOI: 10.1093/annonc/mdx262.018.Peer-Reviewed Original Research90PD Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data
Herbst R, Martin-Liberal J, Calvo E, Isambert N, Bendell J, Cassier P, Jin J, Mi G, Rege J, Paz-Ares L. 90PD Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data. Annals Of Oncology 2017, 28: ii32-ii33. DOI: 10.1093/annonc/mdx091.010.Peer-Reviewed Original Research
2016
LBA38 Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)
Herbst R, Martin-Liberal J, Calvo E, Isambert N, Bendell J, Cassier P, Perez-Gracia J, Yang J, Rege J, Mi G, Ferry D, Paz-Ares L. LBA38 Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P). Annals Of Oncology 2016, 27: vi574. DOI: 10.1093/annonc/mdw435.34.Peer-Reviewed Original ResearchA phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results.
Herbst R, Bendell J, Isambert N, Calvo E, Santana-Davila R, Cassier P, Perez-Gracia J, Yang J, Rege J, Ferry D, Mi G, Chau I. A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results. Journal Of Clinical Oncology 2016, 34: 3056-3056. DOI: 10.1200/jco.2016.34.15_suppl.3056.Peer-Reviewed Original Research